ClinConnect ClinConnect Logo
Search / Trial NCT06769997

Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jan 9, 2025

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Benign Prostatic Hyperplasia Lower Urinary Track Symptoms Bph Luts Optilume Rezum

ClinConnect Summary

This clinical trial is comparing two new treatments for men with benign prostatic hyperplasia (BPH), a condition where the prostate gland enlarges and can cause urinary problems. The two treatments being studied are the Optilume BPH Catheter System and Rezum Water Vapor Therapy. Both aim to help relieve lower urinary symptoms and improve quality of life for men experiencing these issues.

To participate in the trial, men aged 65 to 74 with symptomatic BPH and a prostate size between 30 and 100 grams can apply. However, those with certain conditions, such as previous prostate surgeries or active urinary infections, may not be eligible. Participants will have the opportunity to experience one of these treatments and provide feedback on their symptoms and overall experience. The study is not yet recruiting, but it promises to offer valuable insights into these innovative therapies for BPH.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Male subject with symptomatic BPH.
  • Prostate size 30-100g.
  • Able to complete the study protocol.
  • Exclusion Criteria:
  • Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with follow-up requirements
  • Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
  • Any prior minimally invasive intervention (e.g., TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
  • Confirmed or suspected malignancy of prostate or bladder
  • Active urinary tract infection (UTI) confirmed by culture
  • History of overt urinary incontinence requiring use of pads NOTE: Pad usage for post-micturition dribble is acceptable
  • Presence of confounding diagnoses impacting lower urinary tract symptoms or bladder function (e.g., urethral strictures, bladder neck contracture, neurogenic bladder, detrusor instability, bladder stones, etc.)
  • History of chronic urinary retention (e.g., PVR ≥300mL on two separate occasions, or catheter dependent drainage)
  • Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System
  • Significant obstruction from median lobe (investigator opinion)
  • Disease or other health condition that is not suitable for this study

About Centre Hospitalier De L'université De Montréal (Chum)

The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.

Locations

Montréal, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Naeem Bhojani, MD

Principal Investigator

Centre hospitalier de l'Université de Montréal (CHUM)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported